Tilray, Inc. (NASDAQ: TLRY), a global leader in cannabis research and production, today announced that it partnered with researchers at the Lambert Initiative for Cannabinoid Therapeutics at the University of Sydney to complete a study examining the effects of cannabis on driving and cognitive function.
“The Effects of Medicinal Cannabinoids on Driving” study was a double blind, placebo-controlled study that compared the effects of two varieties of cannabis – a variety containing high levels of THC and a variety containing a 1:1 balanced ratio of THC:CBD – to a placebo, which contained neither THC nor CBD. Tilray supplied the cannabis varieties for the study from its Good Manufacturing Practices (GMP) certified facility in Nanaimo, British Columbia.
“We studied the extent to which cannabis affects driving and specifically, whether CBD moderates the effects of THC,” says Thomas Arkell, a Lambert Initiative researcher, who oversaw the trial. “The two